![figures of different colors](https://phgkb.cdc.gov/GAPPKBImage/images/2013-12_disparities.jpg)
![](https://phgkb.cdc.gov/PHGKB/images/Whats_new.jpg)
Last Posted: Oct 14, 2018
- Hidden 'risk' in polygenic scores: clinical use today could exacerbate health disparities
AR Martin et al, BIORXIV, October 210, 018 - Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives.
de Vries Jeroen K et al. Diabetes, obesity & metabolism 2018 Oct 20 Suppl 324-29 - [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
Moretta Jessica et al. Bulletin du cancer 2018 Sep - Examining How Race, Ethnicity, and Ancestry Data Are Used in Biomedical Research
VL Bonham ret al, JAMA, September 24, 2018 - Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial.
Kinney Anita Y et al. Contemporary clinical trials 2018 Sep 73123-135 - Provider's Perceptions of Barriers and Facilitators for Latinas to Participate in Genetic Cancer Risk Assessment for Hereditary Breast and Ovarian Cancer.
Hurtado-de-Mendoza Alejandra et al. Healthcare (Basel, Switzerland) 2018 Sep 6(3) - Race, Ancestry, and Reporting in Medical Journals
RS Cooper et al, JAMA September 24, 2018 - Should Electronic Health Record-Derived Social and Behavioral Data Be Used in Precision Medicine Research?
Hollister Brittany et al. AMA journal of ethics 2018 Sep 20(9) E873-880 - What Precision Medicine Can Learn from Rare Genetic Disease Research and Translation.
Tabor Holly K et al. AMA journal of ethics 2018 Sep 20(9) E834-840 - Global Inequities in Precision Medicine and Molecular Cancer Research.
Drake Thomas M et al. Frontiers in oncology 2018 8346
No hay comentarios:
Publicar un comentario